13F Holdings
中文EN

KOD Kodiak Sciences Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1468748 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-13.5%
TTM EPS YoY1.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,360.9%
ROA-115.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets94.0%
Debt / equity0.00x
Current ratio1.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-36.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$182.37M$126.09M$206.30M$267.59M$217.34M
SG&A expense$52.02M$60.75M$71.02M$73.79M$49.71M
Operating income-$234.39M-$186.85M-$277.32M-$341.38M-$267.05M
Interest expense$0$0$13,000$18,000$47,000
Pretax income-$229.91M-$176.19M-$260.43M-$333.79M-$266.92M
Income tax$52,000$20,000$33,000$33,000$74,000
Net income-$229.97M-$176.21M-$260.49M-$333.82M-$266.99M
EBITDA-$216.06M-$168.14M-$259.02M-$337.58M-$266.05M
EPS (basic)-4.32-3.35-4.97-6.39-5.16
EPS (diluted)-4.32-3.35-4.97-6.39-5.16
Weighted avg. shares (diluted)53.21M52.58M52.41M52.25M51.79M
Balance sheet
Cash & equivalents$209.86M$168.07M$285.51M$190.43M$731.51M
Short-term investments——$0$288.50M$0
Current assets$214.82M$171.94M$289.31M$486.00M$734.81M
PP&E, net$85.26M$102.22M$120.48M$56.38M$41.33M
Total assets$351.53M$335.58M$479.37M$666.63M$904.22M
Current liabilities$45.53M$25.57M$41.73M$52.50M$64.68M
Total liabilities$194.15M$185.29M$213.59M$230.46M$240.90M
Shareholders' equity$157.38M$150.29M$265.78M$436.17M$663.32M
Shares outstanding61.76M52.73M52.51M52.33M51.83M
Cash flow statement
Operating cash flow-$136.01M-$117.32M-$154.18M-$206.46M-$182.27M
Capital expenditure$506,000$375,000$41.35M$37.02M$17.03M
Free cash flow-$136.51M-$117.69M-$195.53M-$243.48M-$199.30M
Investing cash flow-$506,000-$755,000$249.23M-$336.51M-$38.80M
Financing cash flow$178.30M$501,000$31,000$1.90M$8.18M
Depreciation & amortization$18.33M$18.71M$18.30M$3.80M$1.00M
Stock-based compensation$58.86M$60.21M$88.56M$106.03M$61.38M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.